Serum thiols and cardiovascular risk scores: a combined assessment of transsulfuration pathway components and substrate/product ratios

Journal of Translational Medicine

Marc McEvoy³  John R Attia³  Ciriaco Carru²  Angelo Zinellu²  Arduino A Mangoni¹ 

[1] Division of Applied Medicine, Section of Translational Medical Sciences, School of Medicine and Dentistry, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK;Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43/b, Sassari 07100, Italy;Centre for Clinical Epidemiology & Biostatistics, Hunter Medical Research Institute, School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2308, Australia

关键词: risk assessment;    Epidemiology;    Cardiovascular risk;    Transsulfuration;    Thiols;   

Others  :  827670
DOI  :  10.1186/1479-5876-11-99

 received in 2013-01-13, accepted in 2013-04-09,  发布年份 2013

【 摘 要 】

Background

Serum thiols have shown associations with surrogate markers of cardiovascular disease. However, little information is available on their combined association with validated cardiovascular risk scores for primary prevention at population level. We sought to determine whether individual serum thiol concentrations and substrate/product ratios within the transsulfuration pathway are independently associated with such scores.

Methods

Data on clinical and demographic characteristics, serum thiols (homocysteine, cysteine, taurine, glutamylcysteine, total glutathione and cysteinylglycine) and high-sensitivity C-reactive protein (CRP) were collected from a sample of the Hunter Community Study without previous cardiovascular events [n=350, median age (IQR) = 62 (59–66) years]. Five-year absolute cardiovascular risk score for each subject was calculated using the Framingham Risk Equation.

Results

Median risk score was 7% (IQR 4–10). After adjusting for body mass index, estimated glomerular filtration rate and physical activity regression analysis showed independent associations between cardiovascular risk scores and a) higher serum homocysteine (B 0.066, 95% CI 0.040 to 0.091, P<0.001) and lower cysteine (B −0.003, 95% CI −0.005 to −0.001, P=0.003) and glutathione (B −0.029, 95% CI −0.056 to −0.003, P=0.03) concentrations; and b) higher homocysteine/cysteine (B 0.114, 95% CI 0.066 to 0.161, P<0.001) and lower glutathione/cysteinylglycine (B −1.145, 95% CI −2.030 to −0.260, P=0.011) ratios. No significant associations were observed between cardiovascular risk scores, taurine and CRP.

Conclusions

Serum homocysteine, cysteine and glutathione are independently associated with cardiovascular risk scores at population level. Enzymatic pathways involved in reduced bioconversion of homocysteine into cysteine and increased glutathione degradation might play an important role in such associations.

【 授权许可】

   
2013 Mangoni et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
• [2]Mangoni AA, Jackson SH: Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002, 112:556-565.
• [3]Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, Jacob S, Afonso L: Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011, 58:1025-1033.
• [4]Stipanuk MH: Metabolism of sulfur-containing amino acids. Annu Rev Nutr 1986, 6:179-209.
• [5]Demuth K, Drunat S, Girerd X, Moatti N, Paul JL, Safar M, Boutouyrie P: Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis 2002, 165:167-174.
• [6]Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, Vaccarino V, Alexander RW, Harrison DG, Quyyumi AA: Endothelial function and aminothiol biomarkers of oxidative stress in healthy adults. Hypertension 2008, 52:80-85.
• [7]Dhawan SS, Eshtehardi P, McDaniel MC, Fike LV, Jones DP, Quyyumi AA, Samady H: The role of plasma aminothiols in the prediction of coronary microvascular dysfunction and plaque vulnerability. Atherosclerosis 2011, 219:266-272.
• [8]Lynch SM, Frei B: Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta 1997, 1345:215-221.
• [9]Go YM, Jones DP: Cysteine/cystine redox signaling in cardiovascular disease. Free Radic Biol Med 2011, 50:495-509.
• [10]Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B: Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994, 236:633-641.
• [11]El Khairy L, Ueland PM, Nygard O, Refsum H, Vollset SE: Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study. Am J Clin Nutr 1999, 70:1016-1024.
• [12]McEvoy M, Smith W, D'Este C, Duke J, Peel R, Schofield P, Scott R, Byles J, Henry D, Ewald B: Cohort profile: The Hunter Community Study. Int J Epidemiol 2010, 39:1452-1463.
• [13]Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 1991, 121:293-298.
• [14]National Vascular Disease Prevention Alliance: Consensus statement for the prevention of vascular disease. Aust Fam Physician 2004, 33:235-239.
• [15]Zinellu A, Carru C, Galistu F, Usai MF, Pes GM, Baggio G, Federici G, Deiana L: N-methyl-D-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis 2003, 24:2796-2804.
• [16]Zinellu A, Sotgia S, Scanu B, Chessa R, Gaspa L, Franconi F, Deiana L, Carru C: Taurine determination by capillary electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applications. Amino Acids 2009, 36:35-41.
• [17]Otsuji S, Shibata H, Umeda M: Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 1982, 28:2121-2124.
• [18]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
• [19]Hart TL, Swartz AM, Cashin SE, Strath SJ: How many days of monitoring predict physical activity and sedentary behaviour in older adults? Int J Behav Nutr Phys Act 2011, 8:62. BioMed Central Full Text
• [20]Heesch KC, Hill RL, van Uffelen JG, Brown WJ: Are Active Australia physical activity questions valid for older adults? J Sci Med Sport 2011, 14:233-237.
• [21]Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R: Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010, 170:1622-1631.
• [22]Cheng X: Updating the Relationship Between Hyperhomocysteinemia Lowering Therapy and Cardiovascular Events. Cardiovasc Ther 2012. (http://www.ncbi.nlm.nih.gov/pubmed/23082962 webcite)
• [23]Debreceni B, Debreceni L: Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther 2012, 30:227-233.
• [24]Wald DS, Morris JK, Wald NJ: Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One 2011, 6:e16473.
• [25]van den Brandhof WE, Haks K, Schouten EG, Verhoef P: The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001, 157:403-409.
• [26]El Khairy L, Vollset SE, Refsum H, Ueland PM: Plasma total cysteine, mortality, and cardiovascular disease hospitalizations: the Hordaland Homocysteine Study. Clin Chem 2003, 49:895-900.
• [27]Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
• [28]Weisse K, Brandsch C, Hirche F, Eder K, Stangl GI: Lupin protein isolate and cysteine-supplemented casein reduce calcification of atherosclerotic lesions in apoE-deficient mice. Br J Nutr 2010, 103:180-188.
• [29]Hasegawa S, Ichiyama T, Sonaka I, Ohsaki A, Okada S, Wakiguchi H, Kudo K, Kittaka S, Hara M, Furukawa S: Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cells. Clin Exp Immunol 2012, 167:269-274.
• [30]Finkelstein JD, Martin JJ: Homocysteine. Int J Biochem Cell Biol 2000, 32:385-389.
• [31]Beard RS Jr, Bearden SE: Vascular complications of cystathionine beta-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research. Am J Physiol Heart Circ Physiol 2011, 300:H13-H26.
• [32]Pan LL, Liu XH, Gong QH, Yang HB, Zhu YZ: Role of cystathionine gamma-lyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy? Antioxid Redox Signal 2012, 17:106-118.
• [33]Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL: Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009, 390:191-214.
• [34]Sluik D, Beulens JW, Weikert C, van Dieren S, Spijkerman AM, van der AD, Fritsche A, Joost HG, Boeing H, Nothlings U: Gamma-glutamyltransferase, cardiovascular disease and mortality in individuals with diabetes mellitus. Diabetes Metab Res Rev 2012, 28:284-288.
• [35]Breitling LP, Grandi NC, Hahmann H, Wusten B, Rothenbacher D, Brenner H: Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years. Atherosclerosis 2010, 210:649-655.
• [36]Wojcik OP, Koenig KL, Zeleniuch-Jacquotte A, Costa M, Chen Y: The potential protective effects of taurine on coronary heart disease. Atherosclerosis 2010, 208:19-25.
• [37]Wojcik OP, Koenig KL, Zeleniuch-Jacquotte A, Pearte C, Costa M, Chen Y: Serum taurine and risk of coronary heart disease: a prospective, nested case–control study. Eur J Nutr 2012.
• [38]Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
• [39]Albert MA, Glynn RJ, Ridker PM: Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003, 108:161-165.
• [40]Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M: C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007, 115:981-989.
• [41]de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J: Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 2009, 338:a3083.